HUGE FSD Pharma, Inc.: Year-over-year earnings per share growth for the last twelve months

Official company branding of FSD Pharma (HUGE)

FSD Pharma Inc. (HUGE) is creating a multifaceted biotech ecosystem by combining inflammation and brain research to discover new treatment methods. The protection of Canadian developments under North American law minimizes external risks. Quarterly earnings per share (EPS) growth demonstrates the asset's dynamics, where the current status is 81.60. The company's strategy relies on establishing long-term patents for the therapy of severe disorders, ensuring a stable income from lifelong patient care.

FSD Pharma Inc. (HUGE) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 08/15/2024

Analytical breakdowns for FSD Pharma Inc.

- share price and consensus valuation forecast:
Stock Quotes FSD Pharma|HUGE - Analyst Consensus Forecast
- company stock capitalization data:
Market Value FSD Pharma|HUGE - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share FSD Pharma|HUGE - Total Stockholders' Equity|Market Value to Book Value Ratio fsdpharma.com|HUGE - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity FSD Pharma Inc.|HUGE - Long-Term Liabilities to Capital|Short-Term Debt to Capital FSD Pharma Inc.|HUGE - Company Total Indebtedness|Debt to Book Value FSD Pharma|HUGE - Long-Term Debt|Company Short-Term Debts FSD Pharma|Quick Liquidity fsdpharma.com
- earnings and market multiples details:
HUGE - Net Financial Result|Projected Future Earnings FSD Pharma Inc.|HUGE - Price to Earnings Multiple|Projected Price to Earnings FSD Pharma|HUGE - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FSD Pharma|HUGE - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) FSD Pharma|HUGE - Earnings per share for the trailing year|Quarterly EPS earnings growth fsdpharma.com|HUGE - Earnings growth in current year|Net earnings per share growth forecast for next year FSD Pharma Inc.
- sales volume and revenue indicators:
HUGE - Company Sales Revenue|Company Projected Revenue FSD Pharma Inc.|HUGE - Market Cap to Revenue|Forward P/S Multiple FSD Pharma
Fundamental company analysis:FSD Pharma, HUGE
Manufactured product of FSD Pharma, Inc.

Amid aggressive cost optimization and the divestment of non-core assets, FSD Pharma Inc. (HUGE) has shifted to a model of isolated organic growth. The earnings per share dynamics, reflected on the quarterly EPS change scale, allow investors to smooth out reporting lags through daily recalculations and timely recognize the risk of overpaying for the asset during periods of liquidity shortages.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals plc) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Inc. (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics Corp|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Pharmaceuticals (CNTA)|DYN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Edgewise Therapeutics, Inc. EWTX|Rapport Therapeutics Inc - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Corp|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year larimartx.com LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada Therapeutics Inc. TRDA|Quarterly EPS earnings growth PTHS|MNOV: Year-over-year net earnings per share trend for the last twelve months|Year-over-year earnings per share growth for the last twelve months Serina Therapeutics, Inc. SER|Year-over-year net earnings per share change for the last twelve months bioxceltherapeutics.com (BTAI)|ProMIS - Quarterly EPS earnings growth|APUS (Apimeds Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|AEON (aeonbiopharma.com) - Year-over-year net earnings per share growth for the last 12 months|NLS Pharmaceutics - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Bionomics Ltd.|reatapharma.com - Year-over-year net earnings per share trend for the last twelve months